HCV COMBINATION THERAPIES COMPRISING PEGYLATED INTERFERON, RIBAVIRIN AND TELAPREVIR
摘要
The invention relates to combination therapies for the treatment of hepatitis C virus with telaprevir and pegylated interferon alfa-2a with or without ribavirin. The invention relates to the treatment of patients with bridging fibrosis infected with HCV using the combination therapy.
申请公布号
WO2010093843(A3)
申请公布日期
2010.10.07
申请号
WO2010US23978
申请日期
2010.02.12
申请人
VERTEX PHARMACEUTICALS INCORPORATED;MCNAIR, LINDSAY;KAUFFMAN, ROBERT S.;ALAM, JOHN J.
